Will Ozempic get banned from the Olympics and World Cup?
The use of GLP-1 drugs such as Ozempic and Wegovy is becoming increasingly popular among American adults for weight loss and managing chronic health conditions. Top athletes are also showing interest in these medications, particularly in weight-class sports, as they may aid in rapid weight loss ahead of competition. However, the World Anti-Doping Agency is monitoring the use of GLP-1s in sports, and there is speculation about whether they could become prohibited substances in the future.
- ▪At least one in eight American adults have used a GLP-1 drug to lose weight or manage a chronic health condition.
- ▪The World Anti-Doping Agency added GLP-1s to its monitoring list in 2024, signaling close attention to their use in sports.
- ▪GLP-1s can significantly reduce body weight and body fat, which could benefit athletes in certain sports, but also carry risks such as muscle loss and reduced appetite.
New York Post files mainly under news. We currently carry 10,965 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | New York Post |
| Canonical URL | https://nypost.com/2026/06/22/health/will-ozempic-get-banned-from-the-world-cup-and-the-olympics/ |
| Publication time | Mon, 22 Jun 2026 07:29:00 -0400 |
| Retrieval time | 2026-06-22T11:33:20.108Z |
| Last seen | 2026-06-22T11:33:48.297Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | ki3uaq96L1Eq |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Health Will Ozempic get banned from the Olympics and World Cup? By McKenzie Beard Published June 22, 2026, 7:29 a.m. ET See more of our coverage in your search results. Add The New York Post on Google They’re sweeping the country — and raising questions in the locker room. At least one in eight American adults say they’ve used a GLP-1 drug such as Ozempic or Wegovy to lose weight or manage a chronic health condition, a stunning rise in just a few years. And while top athletes may seem unlikely candidates for the same blockbuster treatments used by everyday dieters, experts say they’re a growing topic of discussion inside the world of professional sports. 6 For athletes in weight-class sports like wrestling, GLP-1s may help with rapid weight loss ahead of competition.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at New York Post.
Discussion
0 commentsMore from New York Post
